Tirzepatide is a dual GIP and GLP-1 receptor agonist, well established in large clinical trials and sold as a prescription product. Prescription titration runs 2.5 mg up to 15 mg weekly over months under supervision; community protocols commonly report 0.5–2 mg weekly, which sits well below the label. Both are reported figures — and with GLP-1-class compounds precision matters, because miscalculated compounded doses have caused documented harm. Research vials come freeze-dried at 5 mg and 10 mg, and the powder has to be dissolved in bacteriostatic water before a syringe reading means anything. The table below runs the concentration for each pairing; the calculator converts any amount into units on the barrel.
Open the Tirzepatide calculator →| Concentration | 1 mL water | 2 mL water | 3 mL water | 5 mL water |
|---|---|---|---|---|
| 5 mg vial | 5,000 mcg/mL | 2,500 mcg/mL | 1,667 mcg/mL | 1,000 mcg/mL |
| 10 mg vial | 10,000 mcg/mL | 5,000 mcg/mL | 3,333 mcg/mL | 2,000 mcg/mL |
Concentration = vial contents ÷ water added. It is the same compound at every volume — more water only means a weaker solution, larger syringe marks that are easier to read, and a larger injection volume. On a standard U-100 insulin syringe, one unit is 0.01 mL at any barrel size.
Calculate a Tirzepatide draw →Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.
Arithmetic, not advice. The calculator performs unit-conversion arithmetic on figures you enter. It does not recommend a dose, a quantity, or a method of administration.
Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.
Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any protocol.